Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study

M. Abdelrahim; A. Esmail; R.D. Kim; S. Patel Arora; J. Arshad; I.A. Kournoutas; C.D. O’Donnell; T.I. Totev; A. Tan; F. Mu; S.M. Seshasayee; S. Hernandez; N.H. Tran

doi:10.1016/j.hpb.2025.07.221

Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study

M. Abdelrahim, A. Esmail, R.D. Kim, S. Patel Arora, J. Arshad, I.A. Kournoutas, C.D. O’Donnell, T.I. Totev, A. Tan, F. Mu, S.M. Seshasayee, S. Hernandez, N.H. Tran

Research output: Contribution to journal › Article › peer-review

Abstract

A+B is the preferred first-line (1L) standard of care for uHCC, with emerging RW evidence supporting its use in a broad patient (pt) cohort. We evaluated pt characteristics, clinical and treatment outcomes in pts treated at five U.S. institutions: Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays Cancer Center, and University of Arizona.

Original language	English (US)
Pages (from-to)	S345
Journal	HPB
Volume	27
DOIs	https://doi.org/10.1016/j.hpb.2025.07.221
State	Published - Oct 3 2025

Divisions

Medical Oncology

Access to Document

10.1016/j.hpb.2025.07.221

Cite this

Abdelrahim, M., Esmail, A., Kim, R. D., Arora, S. P., Arshad, J., Kournoutas, I. A., O’Donnell, C. D., Totev, T. I., Tan, A., Mu, F., Seshasayee, S. M., Hernandez, S., & Tran, N. H. (2025). Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study. HPB, 27, S345. https://doi.org/10.1016/j.hpb.2025.07.221

@article{4eeda74871a34c638bae9ef2e42b437c,

title = "Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study",

abstract = "A+B is the preferred first-line (1L) standard of care for uHCC, with emerging RW evidence supporting its use in a broad patient (pt) cohort. We evaluated pt characteristics, clinical and treatment outcomes in pts treated at five U.S. institutions: Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays Cancer Center, and University of Arizona.",

author = "M. Abdelrahim and A. Esmail and R.D. Kim and Arora, \{S. Patel\} and J. Arshad and I.A. Kournoutas and C.D. O{\textquoteright}Donnell and T.I. Totev and A. Tan and F. Mu and S.M. Seshasayee and S. Hernandez and N.H. Tran",

note = "doi: 10.1016/j.hpb.2025.07.221",

year = "2025",

month = oct,

day = "3",

doi = "10.1016/j.hpb.2025.07.221",

language = "English (US)",

volume = "27",

pages = "S345",

journal = "HPB",

issn = "1365-182X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study

AU - Abdelrahim, M.

AU - Esmail, A.

AU - Kim, R.D.

AU - Arora, S. Patel

AU - Arshad, J.

AU - Kournoutas, I.A.

AU - O’Donnell, C.D.

AU - Totev, T.I.

AU - Tan, A.

AU - Mu, F.

AU - Seshasayee, S.M.

AU - Hernandez, S.

AU - Tran, N.H.

N1 - doi: 10.1016/j.hpb.2025.07.221

PY - 2025/10/3

Y1 - 2025/10/3

N2 - A+B is the preferred first-line (1L) standard of care for uHCC, with emerging RW evidence supporting its use in a broad patient (pt) cohort. We evaluated pt characteristics, clinical and treatment outcomes in pts treated at five U.S. institutions: Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays Cancer Center, and University of Arizona.

AB - A+B is the preferred first-line (1L) standard of care for uHCC, with emerging RW evidence supporting its use in a broad patient (pt) cohort. We evaluated pt characteristics, clinical and treatment outcomes in pts treated at five U.S. institutions: Mayo Clinic, Houston Methodist, Moffitt Cancer Center, Mays Cancer Center, and University of Arizona.

U2 - 10.1016/j.hpb.2025.07.221

DO - 10.1016/j.hpb.2025.07.221

M3 - Article

SN - 1365-182X

VL - 27

SP - S345

JO - HPB

JF - HPB

ER -

Real-world Outcomes of Atezolizumab (A) Plus Bevacizumab (B) for Unresectable Hepatocellular Carcinoma: A Multicenter Study

Abstract

Divisions

Access to Document

Fingerprint

Cite this